vs
Side-by-side financial comparison of HANMI FINANCIAL CORP (HAFC) and Vericel Corp (VCEL). Click either name above to swap in a different company.
Vericel Corp is the larger business by last-quarter revenue ($92.9M vs $71.2M, roughly 1.3× HANMI FINANCIAL CORP). HANMI FINANCIAL CORP runs the higher net margin — 29.8% vs 25.0%, a 4.8% gap on every dollar of revenue. On growth, Vericel Corp posted the faster year-over-year revenue change (23.3% vs 17.1%). HANMI FINANCIAL CORP produced more free cash flow last quarter ($203.7M vs $12.8M). Over the past eight quarters, Vericel Corp's revenue compounded faster (34.6% CAGR vs 10.4%).
Hanmi Bank Corporation is a community bank headquartered in Los Angeles, California, with 35 branches and eight loan production offices in California, Texas, Illinois, New York, New Jersey and Virginia.
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
HAFC vs VCEL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $71.2M | $92.9M |
| Net Profit | $21.2M | $23.2M |
| Gross Margin | — | 78.7% |
| Operating Margin | 29.8% | 24.1% |
| Net Margin | 29.8% | 25.0% |
| Revenue YoY | 17.1% | 23.3% |
| Net Profit YoY | 20.0% | 17.3% |
| EPS (diluted) | $0.70 | $0.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $71.2M | $92.9M | ||
| Q3 25 | $71.0M | $67.5M | ||
| Q2 25 | $65.2M | $63.2M | ||
| Q1 25 | $62.8M | $52.6M | ||
| Q4 24 | $60.8M | $75.4M | ||
| Q3 24 | $58.5M | $57.9M | ||
| Q2 24 | $56.7M | $52.7M | ||
| Q1 24 | $58.4M | $51.3M |
| Q4 25 | $21.2M | $23.2M | ||
| Q3 25 | $22.1M | $5.1M | ||
| Q2 25 | $15.1M | $-553.0K | ||
| Q1 25 | $17.7M | $-11.2M | ||
| Q4 24 | $17.7M | $19.8M | ||
| Q3 24 | $14.9M | $-901.0K | ||
| Q2 24 | $14.5M | $-4.7M | ||
| Q1 24 | $15.2M | $-3.9M |
| Q4 25 | — | 78.7% | ||
| Q3 25 | — | 73.5% | ||
| Q2 25 | — | 73.7% | ||
| Q1 25 | — | 69.0% | ||
| Q4 24 | — | 77.6% | ||
| Q3 24 | — | 71.9% | ||
| Q2 24 | — | 69.5% | ||
| Q1 24 | — | 68.9% |
| Q4 25 | 29.8% | 24.1% | ||
| Q3 25 | 31.1% | 5.1% | ||
| Q2 25 | 23.2% | -3.2% | ||
| Q1 25 | 28.1% | -24.3% | ||
| Q4 24 | 29.1% | 24.5% | ||
| Q3 24 | 25.5% | -4.3% | ||
| Q2 24 | 25.5% | -11.5% | ||
| Q1 24 | 26.0% | -10.7% |
| Q4 25 | 29.8% | 25.0% | ||
| Q3 25 | 31.1% | 7.5% | ||
| Q2 25 | 23.2% | -0.9% | ||
| Q1 25 | 28.1% | -21.4% | ||
| Q4 24 | 29.1% | 26.3% | ||
| Q3 24 | 25.5% | -1.6% | ||
| Q2 24 | 25.5% | -8.9% | ||
| Q1 24 | 26.0% | -7.5% |
| Q4 25 | $0.70 | $0.46 | ||
| Q3 25 | $0.73 | $0.10 | ||
| Q2 25 | $0.50 | $-0.01 | ||
| Q1 25 | $0.58 | $-0.23 | ||
| Q4 24 | $0.58 | $0.40 | ||
| Q3 24 | $0.49 | $-0.02 | ||
| Q2 24 | $0.48 | $-0.10 | ||
| Q1 24 | $0.50 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $137.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $796.4M | $354.6M |
| Total Assets | $7.9B | $488.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $137.5M | ||
| Q3 25 | — | $135.4M | ||
| Q2 25 | — | $116.9M | ||
| Q1 25 | — | $112.9M | ||
| Q4 24 | — | $116.2M | ||
| Q3 24 | — | $101.7M | ||
| Q2 24 | — | $102.5M | ||
| Q1 24 | — | $110.6M |
| Q4 25 | $796.4M | $354.6M | ||
| Q3 25 | $779.5M | $321.9M | ||
| Q2 25 | $762.8M | $306.8M | ||
| Q1 25 | $751.5M | $295.5M | ||
| Q4 24 | $732.2M | $292.0M | ||
| Q3 24 | $736.7M | $257.5M | ||
| Q2 24 | $707.1M | $243.0M | ||
| Q1 24 | $703.1M | $233.9M |
| Q4 25 | $7.9B | $488.0M | ||
| Q3 25 | $7.9B | $453.3M | ||
| Q2 25 | $7.9B | $435.6M | ||
| Q1 25 | $7.7B | $424.6M | ||
| Q4 24 | $7.7B | $432.7M | ||
| Q3 24 | $7.7B | $390.4M | ||
| Q2 24 | $7.6B | $376.8M | ||
| Q1 24 | $7.5B | $356.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $206.0M | $15.0M |
| Free Cash FlowOCF − Capex | $203.7M | $12.8M |
| FCF MarginFCF / Revenue | 286.2% | 13.8% |
| Capex IntensityCapex / Revenue | 3.2% | 2.4% |
| Cash ConversionOCF / Net Profit | 9.70× | 0.65× |
| TTM Free Cash FlowTrailing 4 quarters | $356.1M | $24.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $206.0M | $15.0M | ||
| Q3 25 | $146.9M | $22.1M | ||
| Q2 25 | $-19.0M | $8.2M | ||
| Q1 25 | $25.8M | $6.6M | ||
| Q4 24 | $52.6M | $22.2M | ||
| Q3 24 | $6.7M | $10.2M | ||
| Q2 24 | $2.1M | $18.5M | ||
| Q1 24 | $30.0M | $7.2M |
| Q4 25 | $203.7M | $12.8M | ||
| Q3 25 | $146.4M | $19.5M | ||
| Q2 25 | $-19.6M | $81.0K | ||
| Q1 25 | $25.6M | $-7.6M | ||
| Q4 24 | $49.9M | $8.5M | ||
| Q3 24 | $6.5M | $-9.2M | ||
| Q2 24 | $1.3M | $1.8M | ||
| Q1 24 | $29.2M | $-6.8M |
| Q4 25 | 286.2% | 13.8% | ||
| Q3 25 | 206.3% | 28.8% | ||
| Q2 25 | -30.0% | 0.1% | ||
| Q1 25 | 40.7% | -14.5% | ||
| Q4 24 | 82.1% | 11.2% | ||
| Q3 24 | 11.1% | -15.9% | ||
| Q2 24 | 2.3% | 3.4% | ||
| Q1 24 | 50.0% | -13.3% |
| Q4 25 | 3.2% | 2.4% | ||
| Q3 25 | 0.8% | 3.9% | ||
| Q2 25 | 0.9% | 12.9% | ||
| Q1 25 | 0.4% | 27.0% | ||
| Q4 24 | 4.3% | 18.3% | ||
| Q3 24 | 0.4% | 33.5% | ||
| Q2 24 | 1.4% | 31.8% | ||
| Q1 24 | 1.4% | 27.3% |
| Q4 25 | 9.70× | 0.65× | ||
| Q3 25 | 6.66× | 4.35× | ||
| Q2 25 | -1.26× | — | ||
| Q1 25 | 1.46× | — | ||
| Q4 24 | 2.97× | 1.12× | ||
| Q3 24 | 0.45× | — | ||
| Q2 24 | 0.14× | — | ||
| Q1 24 | 1.98× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HAFC
Segment breakdown not available.
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
